Endomagnetics in £2.1m Fund Raising
News Aug 12, 2013
All the existing investors took part in the latest Series B round: New Wave Ventures, Sarum Capital, UCL Business and Sussex Place Ventures. This brings the total raised by the Company to date to £4.6 million ($7m US).
Endomagnetics has been ramping up sales through Sysmex, its recently appointed distributor for the EMEA region, and new partnerships are being created with hospitals and clinics looking to adopt a more efficient and effective method for sentinel lymph node localisation - a key procedure in breast cancer diagnosis and treatment. Endomagnetics’ SentiMag® system uses advanced sensing technology to detect the location of injected Sienna+® tracer material, eliminating the need for the short-life radioactive alternatives in use today.
“We are delighted that all our investors have demonstrated their continued support for the business through this further fund raising”, said CEO of Endomagnetics Dr Eric Mayes. “Reaction of clinicians to our SentiMag® product has been most enthusiastic.”
Scleroderma Study Offers New Hope For SufferersNews
An unusual autoimmune disease that causes skin and lung damage can be treated effectively by stem cell transplant, a new study found. The approach could represent the first new treatment to improve survival in patients with severe scleroderma in more than four decades.READ MORE
Heart-muscle Patches Created from Human Cells Improve Recovery from Heart AttacksNews
Large, human cardiac-muscle patches created in the lab have been tested, for the first time, on large animals in a heart attack model. This clinically relevant approach showed that the patches significantly improved recovery from heart attack injury.READ MORE